Intrexon Corporation (NYSE:XON)‘s stock had its “buy” rating reaffirmed by Northland Securities in a report issued on Friday. They currently have a $27.00 price target on the biotechnology company’s stock. Northland Securities’ target price would indicate a potential upside of 40.85% from the stock’s previous close.

Other analysts have also recently issued research reports about the company. Griffin Securities reiterated a “buy” rating and set a $55.00 target price on shares of Intrexon Corporation in a research report on Friday. BidaskClub upgraded Intrexon Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. JMP Securities reiterated an “outperform” rating and set a $42.00 target price on shares of Intrexon Corporation in a research report on Thursday. Finally, Zacks Investment Research cut Intrexon Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. Intrexon Corporation has a consensus rating of “Hold” and an average target price of $43.20.

Shares of Intrexon Corporation (NYSE XON) traded down 5.98% on Friday, reaching $19.17. The company had a trading volume of 1,150,135 shares. The company’s market capitalization is $2.31 billion. The company has a 50 day moving average of $19.03 and a 200-day moving average of $21.10. Intrexon Corporation has a 52 week low of $17.03 and a 52 week high of $32.90.

Intrexon Corporation (NYSE:XON) last posted its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.05. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The company had revenue of $54.40 million for the quarter, compared to analysts’ expectations of $57.17 million. During the same period last year, the firm earned ($0.42) earnings per share. Intrexon Corporation’s quarterly revenue was up 3.6% on a year-over-year basis. Analysts predict that Intrexon Corporation will post ($0.87) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/06/intrexon-corporation-xon-stock-rating-reaffirmed-by-northland-securities.html.

In related news, Director Robert B. Shapiro purchased 2,850 shares of the stock in a transaction that occurred on Tuesday, August 22nd. The shares were purchased at an average price of $17.50 per share, with a total value of $49,875.00. Following the completion of the acquisition, the director now directly owns 43,157 shares in the company, valued at approximately $755,247.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Andrew J. Last purchased 2,000 shares of the stock in a transaction that occurred on Monday, August 14th. The shares were bought at an average cost of $19.99 per share, for a total transaction of $39,980.00. Following the acquisition, the chief operating officer now owns 2,000 shares of the company’s stock, valued at $39,980. The disclosure for this purchase can be found here. Insiders have bought 144,569 shares of company stock worth $2,719,429 in the last quarter. Insiders own 55.10% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. grew its holdings in shares of Intrexon Corporation by 60.0% during the first quarter. Goldman Sachs Group Inc. now owns 144,428 shares of the biotechnology company’s stock worth $2,862,000 after buying an additional 54,179 shares during the last quarter. Stifel Financial Corp grew its holdings in shares of Intrexon Corporation by 15.5% during the first quarter. Stifel Financial Corp now owns 60,748 shares of the biotechnology company’s stock worth $1,209,000 after buying an additional 8,135 shares during the last quarter. National Planning Corp grew its holdings in shares of Intrexon Corporation by 13.4% during the second quarter. National Planning Corp now owns 12,958 shares of the biotechnology company’s stock worth $316,000 after buying an additional 1,528 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Intrexon Corporation by 7.1% during the second quarter. Bank of New York Mellon Corp now owns 234,139 shares of the biotechnology company’s stock worth $5,640,000 after buying an additional 15,568 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. grew its holdings in shares of Intrexon Corporation by 3.3% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 82,670 shares of the biotechnology company’s stock worth $1,639,000 after buying an additional 2,645 shares during the last quarter. 82.11% of the stock is currently owned by hedge funds and other institutional investors.

About Intrexon Corporation

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Analyst Recommendations for Intrexon Corporation (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.